Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.60+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HUMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 107.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HUMA — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition On August 12, 2026, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Why it matters: New partnerships could enhance growth and validate the company's strategy. This would improve market outlook.
Supportive ifHumacyte has a new partnership. It is with a large healthcare provider or research group.
Worry ifNo new partnerships are announced. Current partnerships show no progress.
Why it matters: Starting this study is a key step in developing CTEV for CABG. Positive results could enhance Humacyte's pipeline.
Supportive ifHumacyte initiates the Phase 2a study of CTEV in CABG patients in Q3 2026.
Worry ifThe Phase 2a study of CTEV is postponed or canceled.
Why it matters: The offering could provide needed capital for growth and operations. It may signal confidence in future prospects.
Supportive ifA press release says the offering raised more than $50 million.
Worry ifThe offering fails to raise the expected amount or is delayed beyond the planned timeline.
Why it matters: The company needs to meet Nasdaq's listing rules to avoid delisting. This affects investor confidence.
Worry ifA press release shows the company meets Nasdaq's minimum bid price rule.
Less concerning ifAnother notice of delisting or failure to meet listing standards.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$459 on $10,000 · ±4.6% | How much price usually moves either way. |
| Bad day | $1,001 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,782 loss on $10,000 · 77.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better financial stability is important for growth. It will affect how investors feel.
Watch forHumacyte shows better finances. This includes lower losses and more cash flow.
Also watch forThe company reports more losses or worse financial numbers.
Why it matters: Filing the BLA could lead to approval of ATEV for dialysis access. This would be a significant milestone for Humacyte.
Supportive ifHumacyte files the supplemental BLA with the FDA during the second half of 2026.
Worry ifThe company delays the BLA filing beyond 2026.
Why it matters: FDA acceptance would be a key step in bringing the ATEV to market. This could significantly impact Humacyte's growth potential.
Supportive ifThe FDA accepts the new Biologics License Application for the ATEV. This is for dialysis access.
Worry ifThe FDA rejects the supplemental BLA or asks for more data. This delays approval.
Why it matters: Partnerships can enhance market reach and revenue potential for Symvess.
Supportive ifHumacyte announces a new deal for Symvess distribution outside the U.S.
Worry ifNo new partnerships are announced, and existing ones do not expand.
Why it matters: Growing sales show that the market is accepting the product. This could boost investor confidence.
Supportive ifSymvess sales increase to over $0.5 million in the next quarter.
Worry ifSales remain flat or decline from the current $0.4 million.
Why it matters: If the healthcare sector grows faster, it may help Humacyte's market position.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year in the next quarterly report.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: New partnerships could drive growth and improve market position. This is a key management priority.
Supportive ifAn announcement of a new strategic partnership with a major healthcare player.
Worry ifNo new partnerships announced by the next earnings call.
Why it matters: Updates on financial health will show if the company is using its money better.
Watch forQ2 earnings report shows better financial numbers, like fewer losses or more cash flow.
Also watch forQ2 earnings report shows worse financial numbers or more losses.
Why it matters: Fixing compliance issues is key to keeping Humacyte's listing. It also helps maintain investor trust.
Worry ifHumacyte got word from Nasdaq that it meets listing standards again.
Less concerning ifNasdaq issues a further notice of delisting.
Why it matters: Good results could show that CTEV is a new choice for CABG. This would grow Humacyte's market.
Supportive ifThe Phase 2a study of CTEV in CABG patients has started well. It shows positive early results.
Worry ifThe study might have delays or show bad early results.
Why it matters: The public offering's success will affect Humacyte's finances. It will also impact their growth plans.
Supportive ifHumacyte raises at least $10 million from the public offering.
Worry ifThe offering fails to raise the expected capital or is withdrawn.